Science news

<<  return



An analysis of a Canadian registry of patients with atrial fibrillation reveals that one in five treated with oral anticoagulants were also treated with antiplatelet medication. Investigators point out that a "substantial proportion" of patients treated with the dual therapy did not have a compelling reason for adding the antiplatelet, however[1].

Although 60% of patients did have some indication for aspirin, such as coronary or peripheral arterial disease, or even diabetes, which you could argue is no longer an indication for aspirin, 40% of the atrial-fibrillation patients had absolutely no reason for being on aspirin.

Gupta M, Singh N, Cox JL, et al. High rates of concomitant antiplatelet use in patients with atrial fibrillation treated with oral anticoagulation: Insights from the Stroke Prevention and Rhythm Intervention in Atrial Fibrillation (SPRINT-AF) registry. American Heart Association 2014 Scientific Sessions; November 18, 2014; Chicago, IL. Abstract